A study of CLSP-1025 for adults with certain solid tumors
Part of Cancer, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your tumor has a specific p53 R175H mutation confirmed by a lab test.
- You have a certain immune system marker called HLA-A*02:01.
- Your cancer has spread or cannot be removed by surgery, and standard treatments have stopped working or are not available.
- Your performance status is 0 or 1, meaning you are fully active or able to do light work.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
This early-stage trial tests a new immunotherapy called CLSP 5282 designed for patients with advanced solid cancers that have a specific genetic change (KRas G12V mutation) and a matching immune marker (HLA-A*03:01). The treatment aims to help your immune system recognize and attack cancer cells.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This trial tests a new drug (called LG00313112) for people with advanced solid tumors that have a specific genetic change called TP53 Y220C. The drug aims to target this change and may help slow or stop cancer growth.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of two new study drugs (QLS31905 and QL1706) plus chemotherapy against advanced solid tumors that have a specific protein called Claudin18.2. It's for people who have not had any prior treatment for their advanced cancer.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.